Muna Bhanji - 06 Jul 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/ James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
06 Jul 2023
Net transactions value
-$73,373
Form type
4
Filing time
10 Jul 2023, 17:21:43 UTC
Previous filing
21 Jun 2023
Next filing
07 Jul 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale $73,373 -1,867 -13% $39.30 12,526 06 Jul 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported sale of 1,867 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 6, 2023 at each separate price.